Stocks › NVCR
NovoCure Ltd
NVCR·Nasdaq·USD
$14.66
-0.31 (-2.07%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
NVCR
NovoCure Ltd · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NVCRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of NVCR by members of U.S. Congress · 3 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Marie NewmanHouse · D · IL |
NVCRNovoCure Ltd · Stock |
Purchase $15,001 - $50,000 |
Aug 5, 2021 | Jul 2, 2021 | Filing ↗ |
 Donna ShalalaHouse · D · FL |
NVCRNovoCure Ltd · Stock |
Sale $1,001 - $15,000 |
Apr 27, 2020 | Jun 24, 2019 | Filing ↗ |
| Donna ShalalaHouse · D · FL |
NVCRNovoCure Ltd · Stock |
Purchase $1,001 - $15,000 |
Apr 27, 2020 | Jun 19, 2019 | Filing ↗ |
Whale Activity
Position changes in NVCR reported for 2026-06-30 by 10 tracked institutional filers
- Increased7
- New0
- Held0
- Decreased2
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 13.4M | $203.2M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.3M | $95.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.9M | $74.3M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 2.0M | $29.6M | increased |
| Palo Alto Investors LP | 1.3M | $19.4M | — |
| D. E. Shaw & Co., Inc. | 1.0M | $15.5M | increased |
| Point72 Asset Management, L.P. | 803.1K | $12.2M | decreased |
| MILLENNIUM MANAGEMENT LLC | 278.1K | $4.2M | increased |
| CITADEL ADVISORS LLC | 157.2K | $2.4M | increased |
| TWO SIGMA INVESTMENTS, LP | 21.2K | $321K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by NVCR insiders, by quarter · Form 4
Recent Insider Transactions
1,491 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Leonard Frank XChief Executive Officer | Sale | −34.3K | $17.93 | $615K | Jun 4, 2026 | Form 4 ↗ |
| Stafford KristinDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Ocean Allyson JDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Madden Martin J.Director | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Scannell Timothy JDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Hung DavidDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| LEUNG GABRIELDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| HILLEMAN JERYL LDirector | Grant / award | +11.6K | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Stafford KristinDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| Ocean Allyson JDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| Scannell Timothy JDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| Hung DavidDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| HILLEMAN JERYL LDirector | Sale | −2,945 | $15.77 | $46K | Jun 2, 2026 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Option exercise | +21.5K | $11.39 | $245K | Apr 28, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −43.2K | $13.77 | $595K | Mar 5, 2026 | Form 4 ↗ |
| Brackmann ChristophChief Financial Officer | Sale | −6,412 | $13.31 | $85K | Mar 4, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −5,377 | $13.31 | $72K | Mar 4, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding NVCR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.5M | $52.9M | 0.00% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.5M | $38.2M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $21.9M | 0.05% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $18.3M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 617.0K | $9.2M | 0.23% | Jul 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 522.0K | $8.9M | 0.05% | May 31, 2026 |
| iShares U.S. Medical Devices ETF iShares Trust | 493.6K | $7.5M | 0.25% | Jun 30, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 435.5K | $6.6M | 0.05% | Jun 30, 2026 |
| VANGUARD EXPLORER FUND | 410.3K | $6.1M | 0.03% | Jul 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 318.6K | $5.4M | 0.03% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list NVCR's shares (CUSIP G6674U108), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Guy LevySCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗ - Soleus GP, LLCSCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗ - Soleus Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗ - Soleus Capital Group, LLCSCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗ - Soleus Capital, LLCSCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗ - Soleus Capital Master Fund, L.P.SCHEDULE 13G/A · passive (13G) · 10.5M shares9.1%
May 8, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming novocure as client
- WILLIAMS AND JENSEN, PLLCNOVOCURE INC. · 2026 Q2 · PHA, MMM$60K
Filing ↗ - MAYER BROWN LLPNOVOCURE · 2026 Q2 · TRD$20K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCNOVOCURE INC. · 2026 Q2 · MMM, HCR$80K
Filing ↗ - NOVOCURE INC.NOVOCURE INC. · 2026 Q2 · TAR, MMM$160K
Filing ↗ - MAYER BROWN LLPNOVOCURE · 2026 Q1 · TRD$40K
Filing ↗
Government Contracts
Federal awards to novocure · USAspending
$5.5MAwarded · 118 contracts on record
- Department of Veterans AffairsPROSTHETICS OPTUNE TRANSDUCERS$0
Oct 8, 2025 · ↗ - Department of Veterans AffairsOPTUNE DEVICE$50K
Oct 1, 2026 · ↗ - Department of Veterans AffairsPROSTHETIC ORDER - TRANSDUCERS$50K
Oct 1, 2026 · ↗ - Department of Veterans AffairsEXPRESS REPORT: OPTUNE PLUS TRANSDUCERS$99K
Sep 30, 2026 · ↗ - Department of Veterans AffairsOPTUNE PLUS TRANSDUCERS$50K
Sep 29, 2026 · ↗ - Department of Veterans AffairsDEVICE$50K
Sep 23, 2026 · ↗ - Department of Veterans AffairsOPTUNE TRANSDUCER$50K
Sep 25, 2026 · ↗ - Department of Veterans AffairsE014398 SURGICALIMPLANT$50K
Sep 23, 2026 · ↗
U.S. Patents
Recent USPTO applications naming NovoCure Ltd
No USPTO patent applications found for NovoCure Ltd.
Annual Financials
From NVCR's 10-K filings · XBRL
No annual XBRL figures on record for NVCR. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in NVCR's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 9.01Reg FD disclosureOct 1, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeSep 9, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 23, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJun 30, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJun 18, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 5, 2026
EDGAR ↗
About NovoCure Ltd
From SEC EDGAR company records
Industry (SIC 3841)Surgical & Medical Instruments & Apparatus
SectorHealthcare
HeadquartersST. HELIER
SEC CIK0001645113 ↗